Clinical Features and Treatment Outcome of Elderly Multiple Myeloma Patients with Impaired Renal Function

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2019 Apr 21

PMID 31004381

Citations 12

Authors

Jin Chen

Hui Liu

Lijuan Li

Zhaoyun Liu

Jia Song

Guojin Wang

Huaquan Wang

Erbao Ruan

Kai Ding

Zonghong Shao

Rong Fu

Affiliations

Soon will be listed here.

Abstract

Background: Renal impairment (RI) is a most common complication of multiple myeloma (MM), which is associated with an increased risk of early death and worse survival.

Methods: We retrospectively analyzed clinical features and outcomes of 77 MM patients over 70 years old and compared the differences between with and without RI groups.

Results: The percentage of elder MM patients with RI was 61%. Hemoglobin level was a protective factor (OR = 0.954, P = 0.033), while creatinine and hypertension were hazards (OR = 1.288, P < 0.001 and OR = 30.12, P = 0.008). And the percentages of patients with mild-to-moderate RI and moderate-to-severe RI were 40.4% and 59.6%. Complete remission (CR) rate was higher in patients treated with bortezomib (33.3%) than those with non-bortezomib treatment (3.33%) (P = 0.007). Meanwhile, CRrenal was higher in patients with bortezomib (58.3%) than non-bortezomib treatment (22.2%) (P = 0.025). The median OS of the patients with RI treated with bortezomib was longer than those with non-bortezomib regimens (15.0 vs 6.0 months, P = 0.001). The same result was observed in the patients with moderate-to-severe RI (13.0 vs 6.0 months, P = 0.007). The median OS of the patients with RI receiving the bortezomib regimens (15 months) was longer than those with non-bortezomib regimens (6.0 months) (P = 0.001).

Conclusion: Hemoglobin is a protective factor in elder patients with RI, while creatinine and hypertension were hazards. The median OS of elderly patients with RI was worse, and bortezomib can improve the CR rate in these patients.

Citing Articles

Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.

Wei W, Shi H, Chen H, Chen X, Peng R, Yu W Clin Exp Med. 2025; 25(1):48.

PMID: 39904814 PMC: 11794406. DOI: 10.1007/s10238-025-01571-9.

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia.

Chng W, Nagarajan C, Huang S, Malhotra P, Hwang Y, Blunk V Heliyon. 2024; 10(21):e39698.

PMID: 39553611 PMC: 11566861. DOI: 10.1016/j.heliyon.2024.e39698.

Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery.

Cesar B, Braga W, Hamerschlak N, Durao Junior M BMC Nephrol. 2024; 25(1):344.

PMID: 39390432 PMC: 11468068. DOI: 10.1186/s12882-024-03717-5.

Optimal cut-off values and diagnostic significance of clinical laboratory indicators in newly diagnosed multiple myeloma.

Li M, Wu H, Shou C, Peng Y, Song X, Ying W Discov Oncol. 2024; 15(1):477.

PMID: 39331239 PMC: 11436520. DOI: 10.1007/s12672-024-01254-z.

Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma.

Yin J, Qiu J, Zhang Z, Feng B, Shi J, Zheng D J Oncol. 2022; 2022:8628781.

PMID: 35342422 PMC: 8947869. DOI: 10.1155/2022/8628781.

References

Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H . Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica. 2014; 100(3):385-91. PMC: 4349278. DOI: 10.3324/haematol.2014.115204. View

Dimopoulos M, Kastritis E, Rosinol L, Blade J, Ludwig H . Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008; 22(8):1485-93. DOI: 10.1038/leu.2008.131. View

Dimopoulos M, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis M . Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur J Haematol. 2012; 89(1):10-5. DOI: 10.1111/j.1600-0609.2012.01784.x. View

Ludwig H, Bolejack V, Crowley J, Blade J, San Miguel J, Kyle R . Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010; 28(9):1599-605. DOI: 10.1200/JCO.2009.25.2114. View

Chen J, Liu H, Li L, Liu Z, Song J, Wang G . Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function. J Clin Lab Anal. 2019; 33(5):e22888. PMC: 6595344. DOI: 10.1002/jcla.22888. View

Levey A, Stevens L . Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010; 55(4):622-7. PMC: 2846308. DOI: 10.1053/j.ajkd.2010.02.337. View

Kristinsson S, Landgren O, Dickman P, Rangert Derolf A, Bjorkholm M . Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007; 25(15):1993-9. DOI: 10.1200/JCO.2006.09.0100. View

Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F . Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010; 28(30):4635-41. DOI: 10.1200/JCO.2010.28.1238. View

Heher E, Rennke H, Laubach J, Richardson P . Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013; 8(11):2007-17. PMC: 3817918. DOI: 10.2215/CJN.12231212. View

10.

Fouquet G, Gay F, Boyle E, Bringhen S, Larocca A, Facon T . Treatment of Newly Diagnosed Elderly Multiple Myeloma. Cancer Treat Res. 2016; 169:123-143. DOI: 10.1007/978-3-319-40320-5_8. View

11.

San-Miguel J, Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E . Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008; 22(4):842-9. DOI: 10.1038/sj.leu.2405087. View

12.

Hutchins L, Unger J, Crowley J, COLTMAN Jr C, Albain K . Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341(27):2061-7. DOI: 10.1056/NEJM199912303412706. View

13.

Kyle R, Therneau T, Rajkumar S, Larson D, Plevak M, Melton 3rd L . Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer. 2004; 101(11):2667-74. DOI: 10.1002/cncr.20652. View

14.

Phekoo K, Schey S, Richards M, Bevan D, Bell S, Gillett D . A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol. 2004; 127(3):299-304. DOI: 10.1111/j.1365-2141.2004.05207.x. View

15.

Dimopoulos M, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D . The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2012; 27(2):423-9. DOI: 10.1038/leu.2012.182. View

16.

Dimopoulos M, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S . Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010; 28(33):4976-84. DOI: 10.1200/JCO.2010.30.8791. View

17.

Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990; 150(8):1693-5. View

18.

Peyrade F, Gastaud L, Re D, Pacquelet-Cheli S, Thyss A . Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol. 2012; 13(8):e344-52. DOI: 10.1016/S1470-2045(12)70234-6. View

19.

Augustson B, Begum G, Dunn J, Barth N, Davies F, Morgan G . Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005; 23(36):9219-26. DOI: 10.1200/JCO.2005.03.2086. View

20.

Durie B, Harousseau J, Miguel J, Blade J, Barlogie B, Anderson K . International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-73. DOI: 10.1038/sj.leu.2404284. View